Two large trials that dropped radiotherapy from early Hodgkin lymphoma after a clear scan both lost some disease control. Changing the chemotherapy as well is the next attempt.
There is a second-order problem the trials cannot settle quickly. The late-effect figures that justify omitting radiotherapy come from patients treated with mantle fields up to 2000; modern involved-site radiotherapy delivers a fraction of that dose to a fraction of the volume, and nobody knows what its 40-year risk is. The de-escalation may be chasing a harm that has already shrunk, which is an argument for building the survivorship cohorts rather than against running the trial.
Radiotherapy cannot be omitted in early-stage favourable Hodgkin lymphoma on the basis of a negative interim scan without a clinically relevant loss of tumour control. The scan is better at identifying who needs more than at identifying who needs less.
At five years the trial supported using the interim scan to intensify treatment in early Hodgkin lymphoma and not to withhold radiotherapy. The ten-year analysis kept the second conclusion and weakened the first: omitting radiotherapy still lowered progression-free survival, but the gain from switching scan-positive patients to escalated BEACOPP was no longer statistically significant. The 99.0 per cent five-year progression-free survival in the scan-negative favourable group with combined-modality treatment is the number any radiotherapy-sparing strategy has to match.
A main reason so many Hodgkin lymphoma trials are de-escalation trials, and the reason survivors need lifelong surveillance rather than discharge at five years. It is also a warning about assuming that a gentler protocol is a safer one until a cohort has been followed long enough to say.
Shares Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, GHSG HD16, EORTC/LYSA/FIL H10, ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens) and the tag lymphoma-evidence.
Shares Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, GHSG HD16, RADAR, Early-stage classical Hodgkin lymphoma (stage I to II) and the tag lymphoma-evidence.
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), Deauville five-point scale, Dacarbazine, Bleomycin and the tag lymphoma-evidence.
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), Deauville five-point scale, Dacarbazine, Bleomycin and the tag lymphoma-evidence.
Shares Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Brentuximab vedotin, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy and the tag lymphoma-evidence.
Shares Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma, Early-stage classical Hodgkin lymphoma (stage I to II), Radiotherapy, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting and the tag lymphoma-evidence.
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), Deauville five-point scale, Bleomycin, PET/CT and the tag lymphoma-evidence.
Shares ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens), Deauville five-point scale, Bleomycin, PET/CT and the tag lymphoma-evidence.